Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and BRAVE-AA2 Clinical Trials

The study analyzed lipid changes and the use of lipid-lowering medications in patients with severe alopecia areata treated with baricitinib over 152 weeks, using data from the BRAVE-AA1 and BRAVE-AA2 trials. Among 1,303 patients, 43% had hypercholesterolemia at enrollment. Baricitinib treatment was associated with modest increases in total cholesterol, LDL-C, and HDL-C, consistent with JAK inhibitors' class effects. These changes stabilized within a year. Despite the prevalence of hypercholesterolemia, only 6.1% used lipid-lowering medications at baseline, with minimal changes post-baseline. No patients discontinued baricitinib due to lipid-related adverse events, indicating that lipid level increases were manageable.